New anti-diabetic agents
Journal of the Korean Medical Association
;
: 992-997, 2017.
Article
Dans Coréen
| WPRIM
| ID: wpr-158094
ABSTRACT
Diabetes mellitus is characterized by hyperglycemia due to insulin deficiency and/or insulin resistance. Cardiovascular disease (CVD) is a major comorbidity of type 2 diabetes mellitus, and is the most common cause of death in people with diabetes mellitus. Several clinical trials have addressed the long-term effects of near-normoglycemia on CVD, but did not find evidence of an effect. However, some recent clinical trials of sodium glucose cotransporter 2 inhibitors (EMPA-REG [Empagliflozin Cardiovascular Outcomes and Mortality in Type 2 Diabetes Trial], CANVAS [Canagliflozin Cardiovascular Assessment Study]) or glucagon-like peptide-1 agonists (LEADER [Liraglutide Effect and Action in Diabetes Evaluation of Cardiovascular Outcome Results-A Long Term Evaluation], SUSTAIN-6 [Trial to Evaluate Cardiovascular and Other Long-term Outcomes with Semaglutide in Subjects with Type 2 Diabetes]) showed very promising results regarding the prevention of CVD. In this review, I discuss some of these new anti-diabetic agents and present clinical information regarding these drugs.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Sodium
/
Insulinorésistance
/
Maladies cardiovasculaires
/
Comorbidité
/
Mortalité
/
Cause de décès
/
Diabète
/
Diabète de type 2
/
Glucagon-like peptide 1
/
Glucose
Type d'étude:
Étude pronostique
langue:
Coréen
Texte intégral:
Journal of the Korean Medical Association
Année:
2017
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS